Treatment Information

Back

Melanoma treatment details. Chemotherapy.

University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States.

Survival: monthsCountry:United States
Toxiciy Grade:4City/State/Province:Pittsburgh, PA
Treatments:ChemotherapyHospital:University of Pittsburgh Cancer Institute
Drugs:Journal:Link
Date:Nov 2012

Description:

Patients:
This phase 2 study involved 39 metastatic melanoma patients. The median patient age was 63.3 years and 69% were male.

Treatment:
Patients were treated with the chemotherapy agents temozolomide and decitabine.

Toxicities:
The most severe toxicities were of grade 4 and included leukopenia, neutropenia, and blood clots. Grade 2 nausea/vomiting and grade 3 fatigue were also reported.

Results:
The median overall survival was 12.4 months.

Support:
This study was partially supported by the pharmaceutical companies Merck and Eisai.

Correspondence: Dr. H. A. Tawbi; email: [email protected]



Back